Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 60Neoplasms 7Neoplasm Metastasis 6Melanoma 5Carcinoma, Non-Small-Cell Lung 5Neoplasms by Site 4Colorectal Neoplasms 4Breast Diseases 4Ovarian Neoplasms 3Hereditary Sensory and Autonomic Neuropathies 3Endometrial Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Recurrence 2Neuroblastoma 2Multiple Endocrine Neoplasia Type 1 2Lymphoma 2Lung Neoplasms 2Carcinoma, Ovarian Epithelial 2Uterine Cervical Neoplasms 1Unilateral Breast Neoplasms 1Triple Negative Breast Neoplasms 1Teratoma 1Stomach Neoplasms 1Solid Tumors Harboring a BRAF V600 Mutation 1Solid Tumors 1Rhabdomyosarcoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Osteitis Deformans 1Neoplasms, Germ Cell and Embryonal 1

Interventions

ribociclib 1LSZ102 1Alpelisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Advanced or Metastatic ER+ Breast Cancer × ribociclib × Clear all
NCT02734615 2022-08-01

Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers

Novartis

Phase 1 Terminated
199 enrolled
Breast

Advanced or Metastatic ER+ Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡